BPC-157
Gastric pentadecapeptide — VEGF/NO-pathway research reagent, 100+ published studies
Select pack size
Buy nowDelivery in 4 to 7 days. Tracked shipping, discreet packaging — tracking number sent by email once your parcel is on its way.
Delivery in 4 to 7 days · tracked, discreet packaging
Card, Apple Pay, SEPA bank transfer or crypto · 3D-Secure
Lot-specific COA
HPLC >99% — Janoshik analysis on request
Plain, discreet packaging
No contents named on the outer label
Delivery in 4 to 7 days
Tracked shipping across the EU, EEA and Switzerland
About BPC-157
Updated June 2026In stock now. BPC-157 10 mg from $50, >99% HPLC-verified purity, ships in 4 to 7 days with a lot-specific COA on request. For research use only.
In published preclinical models, BPC-157 is studied at roughly 1–10 µg per kg of bodyweight per day, reconstituted from lyophilized powder with bacteriostatic water. These are research-model figures, not human guidance. A 10 mg vial dissolved in 2 mL yields 5 mg/mL. BPC-157 is a research reagent only — not for human or veterinary use.
BPC-157 (Body Protection Compound-157) is a stable pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, derived from the sequence of the human gastric juice protein BPC. It was first isolated and characterized in the 1990s by the research group of Predrag Sikiric at the University of Zagreb. With over 100 peer-reviewed studies, BPC-157 is among the most intensively investigated cytoprotective peptides in preclinical research. The central mechanism of action is based on the promotion of angiogenesis via the VEGF pathway (Vascular Endothelial Growth Factor), with BPC-157 stimulating VEGF receptor-2 phosphorylation and downstream eNOS activation. At the same time, the peptide modulates the nitric oxide (NO) system, providing dual regulation of vascular neogenesis and local blood flow in damaged tissue. Studies by Sikiric et al. (Journal of Physiology Paris, 1999; Current Pharmaceutical Design, 2018) show consistent results in accelerating tissue regeneration in tendons, muscles, ligaments, bones and nervous tissue. In a particularly notable rat experiment (Staresinic et al., Journal of Pharmacological Sciences, 2006), BPC-157 led to full functional recovery of a transected Achilles tendon within 72 days. Also remarkable is the exceptional stability of the peptide in the acidic gastric environment — a rare property among bioactive peptides, enabling both oral and parenteral research routes. Research further suggests neuroprotective effects through modulation of dopaminergic and serotonergic systems, as well as gastroprotective properties via strengthening of the mucosal barrier. BPC-157 also shows cytoprotective action in preclinical models against NSAID-induced gastric mucosal damage and alcohol-induced lesions.
Pricing and pack sizes at a glance: buy BPC-157 for research.
Specifications
- Accelerated tendon regeneration via VEGF-mediated angiogenesis and eNOS activation (Sikiric et al., 2018)
- Gastroprotective effect via NO-system modulation and mucosal barrier reinforcement
- Stability in acidic pH (pH 1–2) — applicable both orally and systemically in research
- Neuroprotective effects via GABA modulation and dopaminergic pathways (Chang et al., Life Sciences 2021)
- Over 100 peer-reviewed studies on cytoprotection and tissue healing across 20+ tissue types
- Full functional recovery of transected Achilles tendon in 72 days in the rat model
- Cytoprotective action against NSAID- and alcohol-induced gastrointestinal lesions
- Upregulation of collagen type I, tenascin and fibronectin at the injury site
- Phase II clinical trial for oral use in ulcerative colitis initiated (NCT05000399)
- Synergistic action with the NO system: reversal of L-NAME and L-arginine induced disturbances
Research context
The most comprehensive review comes from Sikiric et al., "Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract", Current Pharmaceutical Design, Volume 24, Pages 4012–4032 (2018), DOI: 10.2174/1381612824666181112094255. This work summarizes over two decades of research and documents the mechanisms of action in more than 20 different tissue types. Supplementary studies in Journal of Physiology Paris (Sikiric et al., 1999) document fundamental effects on tendon and muscle tissue, including upregulation of growth factor receptors at the injury site. More recent work by Chang et al. (Life Sciences, Volume 284, 119892, 2021) shows neuroprotective effects via GABAergic modulation and regulation of glutamate excitotoxicity. Interaction with the dopaminergic system is published in Sikiric et al. (Regulatory Peptides, Volume 104, Pages 31–40, 2002), where BPC-157 influences dopaminergic neurotransmission in nigrostriatal and mesolimbic pathways. A systematic analysis by Vukojević et al. (Biomedicines, 2022) describes the role of BPC-157 in collagen reorganization and expression of tenascin and fibronectin in tendon tissue. Phase II clinical trials for oral use in ulcerative colitis were initiated in 2021 by Diagen Inc. (ClinicalTrials.gov: NCT05000399).
Storage & handling
Temperature
-20°C (lyophilized) / 2–8°C (reconstituted)
Conditions
Protect from direct light and moisture
Shelf life
18 months (lyophilized, sealed vial)
Reconstitution of BPC-157
Solvent
Bacteriostatic water (0.9% benzyl alcohol)
Volume
1–2 mL
Concentration
10 mg/mL at 1 mL, 5 mg/mL at 2 mL
Step-by-step
- 1Allow the vial and bacteriostatic water to reach room temperature (15–20 minutes).
- 2Use an alcohol swab to disinfect the rubber stoppers of both vials.
- 3Draw the desired amount of bacteriostatic water (1–2 mL) using a sterile 1 mL graduated syringe.
- 4Place the needle against the side of the vial and let the water run slowly down the inner wall.
- 5Gently swirl the vial or roll it between your palms until the powder is fully dissolved. Never shake.
- 6Visually inspect the clear solution for particulates. Do not use if cloudy or if visible particles are present.
- 7Store reconstituted BPC-157 immediately at 2–8°C and use within 21 days.
- 8Disinfect the rubber stopper and use a fresh syringe for each aliquot drawn for assay.
Frequently asked questions
What is BPC-157 and what is it being researched for?
BPC-157 (Body Protection Compound-157) is a stable pentadecapeptide derived from the sequence of the human gastric juice protein. It is investigated in 100+ peer-reviewed studies for tissue regeneration in tendons, muscles, ligaments and nerve tissue.
How is BPC-157 reconstituted and dosed?
The lyophilized powder is reconstituted with bacteriostatic water. Inject the water slowly along the inner wall of the vial and swirl gently. Research protocols typically use microgram-range dosages.
How do I store BPC-157 correctly?
Store lyophilized BPC-157 at -20°C. After reconstitution, keep at 2–8°C and use within 2–3 weeks. Protect from light and moisture to preserve peptide stability.
Is BPC-157 orally stable?
A remarkable property of BPC-157 is its stability in the acidic pH environment of the stomach. Studies show it can be investigated both orally and systemically — a rare property among bioactive peptides.
Can BPC-157 be shipped internationally?
Yes, BPC-157 ships as a research peptide. Shipment is discreet. The product is intended exclusively for research purposes.
Order BPC-157
From $50 · Purity >99%· Delivery in 4 to 7 days
Research reference
Read the BPC-157 research guide
Dosage math, reconstitution, COA checks and protocol context for BPC-157.
